Latest News and Press Releases

Appointments for SVP of Clinical Operations, VP of Translational Science, and Head of Project and Portfolio Management will strengthen Amphista’s clinical development capabilities and accelerate its...

Auron Therapeutics will participate in the 8th Annual Targeted Protein Degradation (TPD) & Induced Proximity Summit in Boston.

Structurally-guided discovery using high-resolution cryo-EM has delivered potent, DCAF16-dependent Targeted Glues™ of SMARCA2, with exquisite selectivity over close homolog, SMARCA4.Rapid, deep and...

Innovative Eclipsys® platform enables rational design of novel Targeted Glues™ with superior drug-like properties  Cambridge, UK, 22 May 2025 – Amphista Therapeutics, a leader in the discovery of...

First-in-class BTK degrader, NX-5948, Granted ODD for WM and assigned nonproprietary name “bexobrutideg” in newly named degrader class of drugs

Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer Appointment supports the Company’s ambitions to advance its portfolio of next generation Targeted Glue™ protein degrader...

Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments Treatment...

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...

Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical data from NX-5948 BTK degrader program Members of the Nurix management...

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...